Blog

Exciting news resonates from DASI Simulations as CMS grants approval for a $1000 reimbursement per report for PrecisionTAVI, marking a pivotal moment for the FDA-cleared predictive modeling product designed for transcatheter aortic valve replacement (TAVR). This landmark decision not only ensures wider accessibility but also offers crucial financial support to hospitals, ultimately contributing to enhanced patient outcomes.

Teri Sirset, CEO, acknowledges the significance of this development, anticipating a transformative impact on the adoption of PrecisionTAVI in hospitals. The decision by CMS is grounded in robust clinical evidence showcasing the positive influence of PrecisionTAVI on patient outcomes, aligning with the broader mission of reshaping healthcare through innovative technology. With over 1,000 patients already benefitting from this groundbreaking approach, PrecisionTAVI’s rapid adoption across leading TAVR centers underscores its role in driving accurate and efficient procedure planning. Dr. Scott Lilly, a member of the DASI Medical Advisory Board, emphasizes the technology’s contribution to shaping the future of clinical outcomes, reinforcing PrecisionTAVI’s acclaim at major cardiology conferences since its FDA clearance in May 2023.